Amylyx Pharmaceuticals (AMLX) Non-Current Assets (2021 - 2026)
Amylyx Pharmaceuticals (AMLX) posted quarterly Non-Current Assets of $8.6 million for Q1 2026, up 142.89% year-over-year from $3.5 million in Q1 2025, and down 4.4% quarter-over-quarter from $9.0 million in Q4 2025.
Amylyx Pharmaceuticals (AMLX) Non-Current Assets (2021 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' Non-Current Assets history runs 6 years deep, the most recent figure standing at $8.6 million for Q1 2026.
- In Q1 2026, Non-Current Assets rose 142.89% year-over-year to $8.6 million; the TTM figure through Mar 2026 stood at $34.6 million (up 85.88% YoY), while the FY2025 annual figure was $9.0 million, up 113.56% from the prior year.
- Non-Current Assets for Q1 2026 stood at $8.6 million, down from $9.0 million in the prior quarter.
- The five-year high for Non-Current Assets was $52.8 million in Q4 2023, with the low at $3.5 million in Q1 2025.
- The 5-year median for Non-Current Assets is $9.0 million (2025), against an average of $13.4 million.
- The sharpest annual moves came in 2022 and 2024: Non-Current Assets jumped 1305.73% in 2022, then plunged 92.04% in 2024.
- Amylyx Pharmaceuticals' Non-Current Assets stood at $9.3 million in 2022, then soared by 466.39% to $52.8 million in 2023, then slumped by 92.04% to $4.2 million in 2024, then soared by 113.56% to $9.0 million in 2025, then declined by 4.4% to $8.6 million in 2026.
- Business Quant data shows AMLX's Non-Current Assets at $8.6 million in Q1 2026, $9.0 million in Q4 2025, and $9.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.65 Bn | 42.68 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 43.09 Bn | 39.44 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.11 Bn | 19.45 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 12.07 Bn | 11.54 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - | 2.96 Bn |
| 10 | Amylyx Pharmaceuticals | 4.36 Bn | 4.36 Bn | - | 8.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.23 Mn |
| Mar 31, 2026 | 8.58 Mn |
| Dec 31, 2025 | 8.97 Mn |
| Sep 30, 2025 | 9.36 Mn |
| Jun 30, 2025 | 7.71 Mn |
| Mar 31, 2025 | 3.53 Mn |
| Dec 31, 2024 | 4.20 Mn |
| Sep 30, 2024 | 5.45 Mn |
| Jun 30, 2024 | 5.44 Mn |
| Mar 31, 2024 | 6.92 Mn |
| Dec 31, 2023 | 52.79 Mn |
| Sep 30, 2023 | 32.47 Mn |
| Jun 30, 2023 | 26.19 Mn |
| Mar 31, 2023 | 18.91 Mn |
| Dec 31, 2022 | 9.32 Mn |
| Sep 30, 2022 | 9.24 Mn |
| Jun 30, 2022 | 9.10 Mn |
| Mar 31, 2022 | 8.95 Mn |
| Dec 31, 2021 | 663,000.00 |